Remove Biopharma Remove Doctors Remove Leads
article thumbnail

I Used AI Tech To Find My Own Cancer Clinical Trial, and You Can Too

MedCity News

My doctor ordered an MRI, which revealed a five-centimeter tumor on the right side, accompanied by lymph-node involvement. I spent the next seven weeks in a state of utter panic, while also trying to maintain a sense of normalcy for my daughter, who was only four at the time, and work full-time leading marketing for a tech startup.

Doctors 317
article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

Continuing advancements within this field deliver new hope to doctors and patients, transforming disease outcomes for previously incurable indications. In 2021, Novo Nordisk Pharmatech, a leading pharmaceutical-grade insulin and Quats product supplier announced plans to enter the enzyme market.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

3 Steps for More Effective HCP Marketing with Insights from Pfizer

PM360

This “synchronization” helps biopharmas such as Pfizer maximize marketing and field efforts across their organizations to improve engagement with healthcare professionals (HCPs). However, many biopharmas fail to synchronize engagement and digital touchpoints in a timely manner for 73% of HCPs. But this change can be doable.

Marketing 105
article thumbnail

Towards ‘smart’ vaccine development and manufacturing

European Pharmaceutical Review

However, the biopharma industries realised that traditional vaccine development and manufacturing techniques, which take around five to 10 years for initial development to large-scale distribution, 1 were inadequate to meet the growing demand for COVID-19 vaccines. The future of platform-based vaccine technology and manufacturing.

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. Can you share an update on the clinical trial for your lead candidate? Hoppin served as lead director of Noria as the two organisations were sold to Bayer Healthcare in June of 2021.

article thumbnail

The use of genomic profiling testing to improve oncology care

pharmaphorum

Dr Prasanth Reddy, head of oncology at LabCorp, tells us how the company works with cancer care teams, biopharma partners, and patients as an integral part of the patient journey from testing to treatment. Across LabCorp , we innovate through science and technology, with access to approximately 2,500 [doctors] and PhDs and over 700 patients.

Patients 106
article thumbnail

Bringing Therapies from Bench to Bedside: Navigating Challenges in the Last Mile

Clarify Health

There is also a looming, time-sensitive reality that biopharma companies face once their products hit the market: they need to recoup the costs of development as quickly as possible before drug patents expire and generics threaten sales. sales, medical science liaisons, etc.).